UMediC Group Berhad (KLSE:UMC)
Malaysia · Delayed Price · Currency is MYR 0.3900
+0.0300 (8.33%)
At close: Aug 11, 2025
Oncternal Therapeutics Income Statement
Financials in millions MYR. Fiscal year is August - July.
Millions MYR. Fiscal year is Aug - Jul.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Apr '25 Apr 30, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 | Jul '21 Jul 31, 2021 | Jul '20 Jul 31, 2020 | 2020 |
| 51.15 | 54.57 | 45.43 | 50.74 | 34.12 | 23.68 | Upgrade | |
Revenue Growth (YoY) | -1.08% | 20.11% | -10.46% | 48.72% | 44.09% | 44.17% | Upgrade |
Cost of Revenue | 29.8 | 31.9 | 26.5 | 32.08 | 21.55 | 16.24 | Upgrade |
Gross Profit | 21.35 | 22.67 | 18.93 | 18.66 | 12.56 | 7.43 | Upgrade |
Selling, General & Admin | 11.66 | 11.43 | 7.64 | 10.03 | 5.88 | 4.67 | Upgrade |
Operating Expenses | 11.68 | 11.46 | 7.63 | 10.01 | 5.89 | 4.59 | Upgrade |
Operating Income | 9.67 | 11.22 | 11.3 | 8.65 | 6.68 | 2.85 | Upgrade |
Interest Expense | -0.09 | -0.14 | -0.25 | -0.81 | -0.73 | -0.45 | Upgrade |
Interest & Investment Income | - | - | - | 0.12 | 0.04 | - | Upgrade |
Earnings From Equity Investments | - | - | - | - | - | -0 | Upgrade |
Other Non Operating Income (Expenses) | 1.52 | 1.56 | 1.88 | 0.53 | 0.55 | 0.64 | Upgrade |
EBT Excluding Unusual Items | 11.1 | 12.64 | 12.93 | 8.48 | 6.54 | 3.04 | Upgrade |
Other Unusual Items | - | - | - | - | 0.01 | 0 | Upgrade |
Pretax Income | 11.1 | 12.64 | 12.93 | 8.48 | 6.55 | 3.04 | Upgrade |
Income Tax Expense | 2.31 | 3.34 | 2.57 | 2.06 | 1.47 | 0.62 | Upgrade |
Earnings From Continuing Operations | 8.79 | 9.3 | 10.36 | 6.43 | 5.09 | 2.42 | Upgrade |
Minority Interest in Earnings | -0.11 | -0.31 | -0.05 | - | - | - | Upgrade |
Net Income | 8.68 | 8.99 | 10.32 | 6.43 | 5.09 | 2.42 | Upgrade |
Net Income to Common | 8.68 | 8.99 | 10.32 | 6.43 | 5.09 | 2.42 | Upgrade |
Net Income Growth | -6.90% | -12.84% | 60.52% | 26.33% | 110.32% | 83.40% | Upgrade |
Shares Outstanding (Basic) | 374 | 374 | 374 | 234 | 374 | 374 | Upgrade |
Shares Outstanding (Diluted) | 374 | 374 | 374 | 234 | 374 | 374 | Upgrade |
Shares Change (YoY) | - | - | 59.51% | -37.31% | - | - | Upgrade |
EPS (Basic) | 0.02 | 0.02 | 0.03 | 0.03 | 0.01 | 0.01 | Upgrade |
EPS (Diluted) | 0.02 | 0.02 | 0.03 | 0.03 | 0.01 | 0.01 | Upgrade |
EPS Growth | -6.74% | -12.84% | 0.64% | 101.51% | 110.33% | 83.44% | Upgrade |
Free Cash Flow | 1.12 | -1.98 | -3.51 | 7.47 | -5.7 | -5.06 | Upgrade |
Free Cash Flow Per Share | 0.00 | -0.01 | -0.01 | 0.03 | -0.01 | -0.01 | Upgrade |
Dividend Per Share | - | - | - | - | - | 0.450 | Upgrade |
Gross Margin | 41.75% | 41.55% | 41.67% | 36.78% | 36.82% | 31.40% | Upgrade |
Operating Margin | 18.90% | 20.55% | 24.88% | 17.04% | 19.57% | 12.03% | Upgrade |
Profit Margin | 16.97% | 16.48% | 22.71% | 12.67% | 14.91% | 10.21% | Upgrade |
Free Cash Flow Margin | 2.19% | -3.63% | -7.72% | 14.72% | -16.71% | -21.39% | Upgrade |
EBITDA | 12.33 | 13.58 | 13.35 | 10.18 | 7.2 | 3.04 | Upgrade |
EBITDA Margin | 24.11% | 24.89% | 29.38% | 20.06% | 21.12% | 12.84% | Upgrade |
D&A For EBITDA | 2.66 | 2.37 | 2.05 | 1.53 | 0.53 | 0.19 | Upgrade |
EBIT | 9.67 | 11.22 | 11.3 | 8.65 | 6.68 | 2.85 | Upgrade |
EBIT Margin | 18.90% | 20.55% | 24.88% | 17.04% | 19.57% | 12.03% | Upgrade |
Effective Tax Rate | 20.79% | 26.45% | 19.86% | 24.24% | 22.38% | 20.50% | Upgrade |
Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.